Pro-Dex (PDEX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Achieved tenth consecutive year of sales growth, with 24% year-over-year increase to $65M in sales for fiscal 2025, and expects continued growth in fiscal 2026 due to a strong backlog, new customers, and ongoing product development.
Annual shareholder meeting scheduled for November 20, 2025, with voting on key proposals including director elections, auditor ratification, executive compensation, and equity plan amendment.
Voting matters and shareholder proposals
Shareholders will vote to elect seven directors, ratify Baker Tilly US, LLP as independent auditor for FY2026, approve executive compensation (say-on-pay), determine frequency of future say-on-pay votes, and amend the 2016 Equity Incentive Plan to extend its term by ten years.
Board recommends voting for all director nominees, for auditor ratification, for executive compensation, for the equity plan amendment, and for annual say-on-pay votes.
Board of directors and corporate governance
Board consists of seven members, with a majority qualifying as independent under Nasdaq rules; roles of Chairman and CEO are separated.
Board committees include Audit, Compensation, Nominating/Corporate Governance, and Investment, all with independent directors except the Investment Committee.
Board held four meetings in FY2025, with all directors attending at least 75% of meetings.
Shareholder communications and director nomination processes are established and disclosed.
Latest events from Pro-Dex
- Strong sales, new products, and investment gains boosted earnings and cash flow.PDEX
Q2 202629 Jan 2026 - Shareholders to vote on board elections, auditor ratification, and executive pay amid record growth.PDEX
Proxy Filing1 Dec 2025 - Annual meeting seeks votes on directors, auditor, pay, and equity plan extension.PDEX
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and say-on-pay vote set for November 21, 2024.PDEX
Proxy Filing1 Dec 2025 - Revenue and net income surged on strong device sales and investment gains, but margin fell.PDEX
Q1 202630 Oct 2025 - Revenue and profit surged on orthopedic product shipments, but inventory controls remain a risk.PDEX
Q2 202516 Oct 2025 - Revenue up 24% and net income quadrupled in fiscal 2025, with strong outlook for 2026.PDEX
Q4 20254 Sep 2025 - Net income rebounded to $2.5M on 25% sales growth and improved gross margin.PDEX
Q1 202513 Jun 2025 - Sales and operating income rose sharply in 2024, but net income dropped on investment losses.PDEX
Q4 202413 Jun 2025